Treosulfan-based conditioning regimens for allogeneic haematopoietic stem cell transplantation in children with non-malignant diseases

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Bone Marrow Transplantation

• Publication date

  2015-08-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/bmt.2015.171PMID 26259076
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treosulfan-based conditioning regimens for allogeneic HSCT in children with acute lymphoblastic leukaemia

  2015cited by this paper
• Pharmacokinetics of Treosulfan in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation

  2014cited by this paper
• Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study.

  2014cited by this paper
• Rapid and sensitive liquid chromatography-tandem mass spectrometry method for determination of protein-free pro-drug treosulfan and its biologically active monoepoxy-transformer in plasma and brain tissue.

  2014cited by this paper
• Treosulfan-based conditioning regimen for children and adolescents with hemophagocytic lymphohistiocytosis

  2014cited by this paper
• Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokinetics.

  2014cited by this paper
• Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial.

  2014cited by this paper
• Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.

  2013cited by this paper
• Improved Clinical Outcomes of High Risk β Thalassemia Major Patients Undergoing a HLA Matched Related Allogeneic Stem Cell Transplant with a Treosulfan Based Conditioning Regimen and Peripheral Blood Stem Cell Grafts

  2013cited by this paper
• Long-term follow-up of children conditioned with Treosulfan: German and Austrian experience

  2013cited by this paper
• Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan.

  2012cited by this paper
• Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience.

  2011cited by this paper
• Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.

  2011cited by this paper
• Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better?

  2010cited by this paper
• High-dose treosulfan in conditioning prior to hematopoietic stem cell transplantation

  2010cited by this paper
• Immune deficiencies , infection , and systemic immune disorders Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe : Entering a new century , do we do better ?

  2010cited by this paper
• Treosulphan as an alternative to busulphan for myeloablative conditioning in paediatric allogeneic transplantation

  2008cited by this paper
• Treosulfan‐containing regimens achieve high rates of engraftment associated with low transplant morbidity and mortality in children with non‐malignant disease and significant co‐morbidities

  2008cited by this paper
• Myeloablative and immunosuppressive properties of treosulfan in mice.

  2006cited by this paper
• Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications

  2005cited by this paper
• Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation.

  2004cited by this paper
• Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: Regression modeling

  2001cited by this paper
• Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: Unadjusted analysis

  2001cited by this paper
• A Proportional Hazards Model for the Subdistribution of a Competing Risk

  1999cited by this paper
• A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk

  1988cited by this paper
• CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S

  1974cited by this paper

• Treosulfan-based conditioning strategies in older or frail patients undergoing allogeneic hematopoietic cell transplantation

  2026cites this paper
• Abatacept improves posttransplant survival and reduces endothelial injury syndromes in β-thalassemia major

  2025cites this paper
• Risk factors for hematopoietic stem cell transplantation in inborn errors of immunity.

  2025cites this paper
• Treosulfan- versus busulfan-based conditioning in allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: a single-center retrospective propensity score-matched cohort study.

  2024cites this paper
• Outcomes from hematopoietic stem cell transplantation following treosulfan‐based conditioning: A clinical and pharmacokinetic analysis

  2024cites this paper
• The use of thiotepa in reduced toxicity conditioning regimens before hematopoietic stem cell transplantation in primary immunodeficiencies

  2024cites this paper
• The impact of Treosulfan‐based conditioning for inborn errors of immunity: Is dose monitoring crucial?

  2023cites this paper
• Updates in hematopoietic cell transplant and cellular therapies that enhance the risk for opportunistic infections

  2023cites this paper
• Personalized hematopoietic stem cell transplantation for inborn errors of immunity

  2023cites this paper
• Feasibility study of busulfan, fludarabine, and thiotepa conditioning regimen for allogeneic hematopoietic stemcell transplantationfor children and young adults with nonmalignant disorders

  2023cites this paper
• Treosulfan Exposure Predicts Thalassemia-Free Survival in Patients with Beta Thalassemia Major Undergoing Allogeneic Hematopoietic Cell Transplantation

  2023influential citation
• Treosulfan vs busulfan conditioning for allogeneic bmt in children with nonmalignant disease: a randomized phase 2 trial

  2023cites this paper
• Toxic complications of high doses of treîsulfan in children: experience of the N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia

  2023cites this paper
• Transplant for non-malignant disorders: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee report on the role of alternative donors, stem cell sources and graft engineering.

  2023cites this paper
• Treosulfan-based conditioning regimen in pediatric hematopoietic stem cell transplantation: A retrospective analysis on behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC).

  2023cites this paper
• Across the Myeloablative Spectrum: Hematopoietic Cell Transplant Conditioning Regimens for Pediatric Patients with Sickle Cell Disease

  2022cites this paper
• A Short Review on Growth and Endocrine Long-term Complications in Children and Adolescents with β-Thalassemia Major: Conventional Treatment versus Hematopoietic Stem Cell Transplantation

  2022cites this paper
• Busulfan–fludarabine- or treosulfan–fludarabine-based myeloablative conditioning for children with thalassemia major

  2022cites this paper
• Comparative study of treosulfan plus Fludarabine (FT14) with busulfan plus Fludarabine (FB4) for acute myeloid leukemia in first or second complete remission: An analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP)

  2022cites this paper
• Treosulfan-Based Conditioning in Matched Family, Unrelated and Haploidentical Hematopoietic Stem Cell Transplantation for Genetic Hemophagocytic Lymphohistiocytosis: Experience and Outcomes over 10 Years from India

  2021cites this paper
• Lineage-Specific Chimerism and Outcome After Hematopoietic Stem Cell Transplantation for DOCK8 Deficiency

  2021cites this paper
• Impact of in vivo lymphodepletion on outcome in children with non-malignant disorders receiving peripheral blood stem cell transplantation.

  2021cites this paper
• Survival advantage of treosulfan plus fludarabine before allogeneic hematopoietic cell transplantation for older or comorbid patients with myeloid malignancies.

  2021cites this paper
• EBMT/ESID inborn errors working party guidelines for hematopoietic stem cell transplantation for inborn errors of immunity

  2021cites this paper
• Impact of treosulfan exposure on early and long-term clinical outcome in pediatric allogeneic HSCT recipients: a prospective multicenter study.

  2021cites this paper
• Treosulfan-Based Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Pediatric Patients with Hemophagocytic Lymphohistiocytosis

  2021cites this paper
• Treosulfan-based conditioning for inborn errors of immunity

  2021cites this paper
• Treosulfan–fludarabine–thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies

  2020cites this paper
• Prospective study of a novel, radiation-free, reduced-intensity bone marrow transplantation platform for primary immunodeficiency diseases.

  2020cites this paper
• Acute toxicity and outcome among pediatric allogeneic hematopoietic transplant patients conditioned with treosulfan-based regimens

  2020cites this paper
• Az allogén vérképző őssejtátültetés korai szövődményei gyermekkorban

  2020cites this paper
• Treosulfan – fl udarabine – thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies

  2020cites this paper
• Investigation of the Influences on Decision-Making Algorithms in Allogeneic Stem Cell Transplantation in Different Groups of Pediatric Nonmalignant Diseases

  2020influential citation
• Priorities for Improving Outcomes for Non-Malignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network.

  2020cites this paper
• HSCT in Benign Hematological Disorders

  2020cites this paper
• Risk factors for mixed chimerism in children with hemophagocytic lymphohistiocytosis after reduced toxicity conditioning

  2020cites this paper
• Treosulfan-Based Conditioning Regimen in Haematopoietic Stem Cell Transplantation with TCRαβ/CD19 Depletion in Nijmegen Breakage Syndrome.

  2020cites this paper
• Anti-Müllerian hormone and Inhibin B after stem cell transplant in childhood: a comparison of myeloablative, reduced intensity and treosulfan-based chemotherapy regimens

  2020cites this paper
• Imatinib melylate as second‐line treatment of bronchiolitis obliterans after allogenic hematopoietic stem cell transplantation in children

  2020cites this paper
• Skin toxicity following treosulfan‐thiotepa‐fludarabine‐based conditioning regimen in non‐malignant pediatric patients undergoing hematopoietic stem cell transplantation

  2019cites this paper
• T-cell replete haploidentical bone marrow transplantation and post-transplant cyclophosphamide for patients with inborn errors

  2019cites this paper
• Hematopoietic Stem Cell Transplantation Beyond Severe Combined Immunodeficiency: Seeking a Cure for Primary Immunodeficiency.

  2019cites this paper
• Analysis of donor-associated factors in unrelated transplantations of hematopoietic stem cells in children with non-malignant diseases

  2019cites this paper
• Severe vascular and neurological complications after hematopoietic stem cell transplantation with reduced intensity conditioning

  2019cites this paper
• Population pharmacokinetics of treosulfan in paediatric patients undergoing hematopoietic stem cell transplantation

  2019cites this paper
• Gonadal Function after Busulfan Compared with Treosulfan in Children and Adolescents Undergoing Allogeneic Hematopoietic Stem Cell Transplant.

  2019cites this paper
• Анализ донор-ассоциированных факторов при неродственных трансплантациях гемопоэтических стволовых клеток у детей с незлокачественными заболеваниями

  2019cites this paper
• HLA-haploidentical hematopoietic stem cell transplantation in pediatric patients with hemoglobinopathies: current practice and new approaches

  2019cites this paper
• Haematopoietic Stem Cell Transplantation for Primary Haemophagocytic Lymphohistiocytosis

  2019cites this paper
• Conditioning Regimens for Hematopoietic Cell Transplantation in Primary Immunodeficiency

  2019cites this paper
• Hematopoietic cell transplantation in primary immunodeficiency – conventional and emerging indications

  2018cites this paper
• Hematopoietic Stem Cell Transplantation for Primary Immunodeficiency Disorders: Experience from a Referral Center in India

  2018cites this paper
• Outcome of treosulfan‐based reduced‐toxicity conditioning regimens for HSCT in high‐risk patients with primary immune deficiencies

  2018cites this paper
• Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency.

  2018cites this paper
• Successful Sequential Liver and Hematopoietic Stem Cell Transplantation in a Child With CD40 Ligand Deficiency and Cryptosporidium-Induced Liver Cirrhosis

  2018cites this paper
• Preparing the Patient for HSCT: Conditioning Regimens and Their Scientific Rationale

  2018cites this paper
• Mini Review: Screening and Management of Late Effects in Patients with Severe Combined Immunodeficiency after Allogeneic Hematopoietic Cell Transplantation

  2018cites this paper
• Bone Marrow Transplantation after Nonmyeloablative Treosulfan Conditioning Is Curative in a Murine Model of Sickle Cell Disease.

  2018cites this paper
• Allogeneic Hematopoietic Cell Transplantation for Chronic Granulomatous Disease: Controversies and State of the Art

  2018cites this paper
• Disposition of treosulfan and its active monoepoxide in a bone marrow, liver, lungs, brain, and muscle: Studies in a rat model with clinical relevance

  2017influential citation
• Population pharmacokinetics of treosulfan and development of a limited sampling strategy in children prior to hematopoietic stem cell transplantation

  2017cites this paper
• Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Stem Cell Transplantation (HCT) for Severe Combined Immunodeficiency Patients: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects afte

  2017cites this paper
• Survival Advantage and Comparable Toxicity in Reduced-Toxicity Treosulfan-Based versus Reduced-Intensity Busulfan-Based Conditioning Regimen in Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients after Allogeneic Hematopoietic Cell Transplantation.

  2017cites this paper
• Allogeneic Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for Treatment of Marrow Failure Disorders.

  2017cites this paper
• Treosulfan-Based Conditioning Regimen in Sibling and Alternative Donor Hematopoietic Stem Cell Transplantation for Children with Sickle Cell Disease

  2017cites this paper
• Long-term outcome of hematopoietic stem cell transplantation for IL2RG/JAK3 SCID: a cohort report.

  2017cites this paper
• Treosulfan and Fludarabine Conditioning for Hematopoietic Stem Cell Transplantation in Children with Primary Immunodeficiency: UK Experience.

  2017cites this paper
• Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study

  2017cites this paper
• High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric HSCT: a prospective multicentre study

  2017cites this paper
• Long term outcomes of severe combined immunodeficiency: therapy implications

  2017cites this paper
• Long‐term outcome after a treosulfan‐based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

  2017cites this paper
• Disease-specific hematopoietic stem cell transplantation in children with inherited bone marrow failure syndromes

  2017cites this paper
• Unrelated Hematopoietic Cell Transplantation in a Patient with Combined Immunodeficiency with Granulomatous Disease and Autoimmunity Secondary to RAG Deficiency

  2016cites this paper
• Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience.

  2016cites this paper
• Primary Immune Deficiency Treatment Consortium (PIDTC) update.

  2016cites this paper
• Penetration of Treosulfan and its Active Monoepoxide Transformation Product into Central Nervous System of Juvenile and Young Adult Rats

  2015cites this paper
• Recent advances in treatment of severe primary immunodeficiencies

  2015cites this paper
• Primary Immune Deficiency Treatment Consortium (PIDTC) report.

  2014cites this paper
• Journal Pre-proof Impact of in vivo lymphodepletion on outcome in children with non-malignant disorders receiving peripheral blood stem cell transplantation

  year unknowncites this paper